knowledge -WSS

knowledge

author：knowledge 2025-10-01 02:14:03 - browse：379

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox.

Hello, friends! I’m in San Francisco for the STAT Breakthrough Summit. Later today, I’ll be “fireside chatting” with Cytokinetics CEO Robert Blum. It’s not too late to join us virtually. Check out details here.

It’s a travel-shortened week for me, so in this newsletter, I decided to dive deep into PDS Biotech and its experimental drug for head and neck cancer. PDS is what I’d call a biotech cult stock.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Why getting cancer drugs just got harder for rural patients

hotspot

WSS

Congress gives doctors Medicare pay bump

How to fix the rural physician shortage in the U.S.

Midwives could help bridge maternal health disparities in the U.S.

Why the drug industry's warnings on the IRA's impact fall short

Neurocrine congenital adrenal hyperplasia trial succeeds

International team creates first chimeric human

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

leisure time

Sports medicine is finally prioritizing gender equality

Fed up with FDA, ALS advocates consider a take

How one medical school became remarkably diverse

FDA weighs limits of animal data in assessing artificial wombs

Medical leaders decry Supreme Court decision on affirmative action

Why the drug industry's warnings on the IRA's impact fall short

Apple is now the first public company to be valued at $3 trillion

Pfizer highlights cancer drugs it thinks could reignite investor interest

Anesthesiologist group: stop taking Ozempic before surgery

Assistant physicians can help address the primary care shortage

hotspot

Midwives could help bridge maternal health disparities in the U.S.

House panel takes first step toward fixing drug shortages

Medicare to pay more for cardiac rehab in hospital outpatient clinics

Covid’s new normal has set in amid another rise in cases

David Liu startup to focus on CRISPR delivery

Clinical trials giant ICON acquires HumanFirst

knowledge

Wikipedia

hotspot

knowledge